Omalizumab in the treatment of allergy and asthma

By Lanier Bob   Carr Warner  

Therapy, Vol. 1, Iss. 1, 2004-09 ,pp. : 25-30

Future Medicine

Access to resources Recommend Favorite

Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

By  

INTERNAL MEDICINE JOURNAL, Vol. 46, Iss. 9, 2016-09 ,pp. : 1054-1062

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy

By  

International Archives of Allergy and Immunology, Vol. 151, Iss. 4, 2009-10 ,pp. : 275-284

Karger

Access to resources Recommend Favorite

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. S1, 2015-03 ,pp. : 734-743

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design

By White Thomas J   Clark Andrew G   Broder Samuel  

Personalized Medicine, Vol. 3, Iss. 2, 2006-05 ,pp. : 177-185

Future Medicine

Access to resources Recommend Favorite